Точка Синхронізації

Danish pharmaceutical giant Novo Nordisk filed a patent infringement lawsuit against the telehealth firm Hims & Hers Health Inc. in a US federal court on Thursday, seeking to block the sale of unauthorized compounded versions of its popular weight-loss drug Wegovy. The legal action centers on the unauthorized production of semaglutide, the active ingredient in Wegovy and Ozempic, which Hims & Hers has been offering at a lower cost to consumers amid ongoing global supply shortages. Novo Nordisk argues that these "knock-off" versions bypass regulatory safeguards and violate intellectual property protections established by years of research and development. The conflict escalates a growing tension between major drug manufacturers and a burgeoning industry of compounding pharmacies and telehealth providers. Hims & Hers reacted sharply to the litigation, characterizing the lawsuit as a "blatant attack" on patients' ability to access essential treatments during a public health shortage. The telehealth company maintains that federal regulations allow for the compounding of medications when a branded drug is officially listed as being in short supply by the Food and Drug Administration (FDA), a status that semaglutide has held for much of the past two years. Novo Nordisk, however, contends that the safety and efficacy of these compounded alternatives have not been verified through the same rigorous clinical trials required for Wegovy. The company is seeking both a permanent injunction to stop the sale of these competing products and unspecified monetary damages. This legal maneuver follows dozens of similar lawsuits filed by Novo Nordisk against medical spas and weight-loss clinics, signaling a comprehensive legal campaign to regain full control over the market for GLP-1 receptor agonists as supply chains begin to stabilize.